[UK, En] English [Country Language]

Menu

Close

ResourcesInteractions Finder
PAXLOVID™ (nirmatrelvir; ritonavir) is authorised in GEORGIA 

On February 24,2022 the LEPL Regulation Agency for Medical and Pharmaceutical Activities of the Ministry of Internally Displaced Persons from Occupied Territories, Labour, Health and Social Affairs of Georgia has granted  Emergency Use Authorization for PAXLOVID™ for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Summary of Product Characteristics Package Leaflet: Information for the Patient Ensuring the Authenticity  Interactions Finder Report an Adverse Event
Watch the video
PAXLOVID™ Summary of Product Characteristics (SmPC)

View the full Summary of Product Characteristics, which includes dosing, clinical data, and safety information. 

Click here
PAXLOVID™ Package Leaflet: Information for the Patient

View the Package Leaflet, which contains important information for the patient about how to take PAXLOVID™ and what to expect from treatment.

Click here
Ensuring the Authenticity of PAXLOVID™ 

Authentic PAXLOVID™ from Pfizer will include the Pfizer name on the carton. Paxlovid tablets are available in 5 daily‑dose blister cards with a total of 30 tablets packaged in a carton.
Each daily blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each) and indicates which tablets need to be taken in the morning and evening.

Nirmatrelvir 150 mg film-coated tablets are pink, oval-shaped and debossed with ‘PFE’ on one side and ‘3CL’ on the other side.
Ritonavir 100 mg film-coated tablets are white to off white, capsule shaped and debossed with ‘H’ on one side and ‘R9’ on the other side.

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.
The outer carton of the box has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish. 

Next PageInteractions Finder

This site is intended only for healthcare professionals in Georgia. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only. 

Copyright © 2021 Pfizer Inc. All rights reserved. PP-PAX-GEO-0009
For GEORGIA Healthcare Professionals

These pages are not intended for patients or for members of the general public.

I confirm that I am a healthcare professional resident in GEORGIA.

If you select 'No', you will be redirected to covid19oralrx.com where you will be able to access reference information on PAXLOVID™ (nirmatrelvir; ritonavir)

            Yes                       No